.svg)
What ANA test negative means
An ANA test negative result indicates that your blood contains very low levels of antinuclear antibodies. These antibodies form when your immune system mistakenly identifies your own cell nuclei as foreign invaders.
The test uses a dilution method, typically starting at 1:80 or 1:160. A negative result means antibodies weren't detected at these dilution levels. Most laboratories consider patterns visible at 1:80 dilution as positive, while anything below this threshold gets reported as negative.
This pattern may be associated with different biomarker profiles than those typically seen in systemic autoimmune rheumatic diseases. Research suggests lupus may be associated with positive ANA results in studies. Studies indicate scleroderma and mixed connective tissue disease also correlate strongly with positive ANA tests.
However, your immune system is complex. Some autoimmune conditions primarily affect specific organs rather than causing systemic inflammation. Organ-specific autoimmune conditions like Hashimoto's thyroiditis are typically identified through condition-specific antibodies (such as thyroid peroxidase and thyroglobulin) rather than ANA screening.
How to interpret ANA test negative
Context shapes interpretation. If you're experiencing joint pain, fatigue, or skin rashes that prompted ANA testing, a negative result shifts the focus away from major autoimmune diseases toward other explanations. Discuss with your care team how these findings relate to your specific symptoms.
Your symptoms might stem from viral infections, medication side effects, or non-autoimmune inflammatory conditions. Fibromyalgia, for instance, can mimic lupus symptoms but typically shows negative ANA results.
Consider the timing of your test. Early-stage autoimmune diseases sometimes produce negative ANA results before antibody levels become detectable. If clinical suspicion remains high despite negative results, your care team might recommend retesting after a clinically appropriate interval.
The test's sensitivity varies by condition. While lupus rarely presents with persistent negative ANA results, other conditions like rheumatoid arthritis show positive ANA in a substantial minority of cases, with reported rates varying widely across studies. Your care team will evaluate ANA results alongside other biomarkers and clinical findings to build a complete picture.
What can influence ANA test negative
Several factors can affect ANA test accuracy and interpretation. Medications represent the most common influence. Immunosuppressive drugs, including corticosteroids and disease-modifying antirheumatic drugs (DMARDs), can suppress antibody production and create false negative results.
Timing matters significantly. Some people develop detectable ANA levels months or years before clinical symptoms appear, while others show symptoms before antibodies become measurable. This window creates potential for both false negatives and confusion about disease progression.
Technical factors also play a role. Different laboratories use varying dilution thresholds and substrate materials for ANA testing. Some labs report negative results at 1:40 dilution, while others require 1:80 or higher for positive classification.
Age influences baseline ANA levels. Healthy older adults sometimes develop low-level positive ANA results without any autoimmune disease, while younger people with autoimmune conditions might initially test negative. Your care team considers these age-related patterns when interpreting results.
Related context that changes the picture
Other biomarkers can reveal autoimmune activity despite negative ANA results. Rheumatoid factor (RF) and anti-CCP antibodies help identify rheumatoid arthritis independently of ANA status. Thyroid antibodies, including thyroid peroxidase (TPO) and thyroglobulin antibodies, help identify autoimmune thyroid conditions.
Complement levels provide additional insight. Low C3 and C4 complement proteins suggest ongoing immune system activation, even with negative ANA results. Inflammatory markers like C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) can indicate systemic inflammation from non-autoimmune sources.
Specific antibody testing becomes crucial when clinical suspicion remains high. Anti-Ro/SSA and anti-La/SSB antibodies can be positive in lupus cases with negative ANA screening tests. Similarly, anti-mitochondrial antibodies help identify primary biliary cholangitis regardless of ANA status.
Your symptom pattern provides essential context. Joint morning stiffness lasting over an hour, malar (butterfly) rash, or dry eyes and mouth might warrant additional testing despite negative ANA results. The combination of clinical findings and biomarker patterns guides next steps in evaluation. Discuss with your care team how these patterns might relate to your specific situation.
Take control of your health journey
Understanding your ana test negative result is just one piece of your health puzzle. While this result may be associated with reduced risk of major autoimmune diseases, comprehensive health monitoring requires looking at immune markers alongside metabolic, cardiovascular, and hormonal indicators.
Superpower's blood panels provide this complete picture by measuring immune system biomarkers like CRP and complement levels alongside 90+ other crucial health indicators. Instead of wondering whether isolated symptoms connect to broader health patterns, you get clear insights into how your immune system functions within your overall health landscape.
Get your Superpower Blood Panel today and transform uncertainty into actionable health insights.
FAQs
A negative ANA test means your blood contains very low levels of antinuclear antibodies, making major systemic autoimmune diseases like lupus highly unlikely. However, it doesn't rule out all autoimmune conditions, particularly those affecting specific organs.
Yes, some autoimmune diseases can present with negative ANA results. Organ-specific autoimmune conditions are typically identified through condition-specific antibodies rather than ANA screening — for example, Hashimoto's thyroiditis is diagnosed using thyroid peroxidase and thyroglobulin antibodies rather than ANA.
Medications like immunosuppressive drugs and corticosteroids can suppress antibody production and create false negative results. Timing also matters, as some people develop symptoms before antibodies become detectable, while others show antibodies before symptoms appear.
Lupus with persistently negative ANA results is uncommon, occurring in approximately 5-7% of cases at diagnosis. However, early-stage lupus might initially show negative results before antibody levels become detectable, which is why retesting may be recommended if clinical suspicion remains high.
When symptoms persist despite a negative ANA, your care team may order additional specific antibody tests. Rheumatoid factor and anti-CCP antibodies can identify rheumatoid arthritis independently of ANA status. Thyroid antibodies including thyroid peroxidase and thyroglobulin antibodies help identify autoimmune thyroid conditions. Complement levels C3 and C4 and inflammatory markers like CRP and ESR can also reveal immune system activity not captured by ANA testing.
No. ANA testing is designed to screen for systemic autoimmune rheumatic diseases and is not the standard tool for diagnosing Hashimoto's thyroiditis. Organ-specific autoimmune conditions like Hashimoto's are identified through their own condition-specific antibodies — thyroid peroxidase and thyroglobulin antibodies — rather than ANA screening. A negative ANA result does not address thyroid autoimmunity.
References
- Leuchten, N., Hoyer, A., Brinks, R., Schoels, M., Schneider, M., Smolen, J., Johnson, S. R., Daikh, D., Dörner, T., Aringer, M., Bertsias, G., & Systemic Lupus Erythematosus Classification Criteria Steering Committee (2018). Performance of Antinuclear Antibodies for Classifying Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Regression of Diagnostic Data. Arthritis care & research, 70(3), 428-438. https://doi.org/10.1002/acr.23292
- Mariz, H. A., Sato, E. I., Barbosa, S. H., Rodrigues, S. H., Dellavance, A., & Andrade, L. E. (2011). Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis and rheumatism, 63(1), 191-200. https://doi.org/10.1002/art.30084
- Aringer, M., Costenbader, K., Daikh, D., Brinks, R., Mosca, M., Ramsey-Goldman, R., Smolen, J. S., Wofsy, D., Boumpas, D. T., Kamen, D. L., Jayne, D., Cervera, R., Costedoat-Chalumeau, N., Diamond, B., Gladman, D. D., Hahn, B., Hiepe, F., Jacobsen, S., Khanna, D., ... Johnson, S. R. (2019). 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis & rheumatology (Hoboken, N.J.), 71(9), 1400-1412. https://doi.org/10.1002/art.40930
- Pisetsky, D. S., & Lipsky, P. E. (2020). New insights into the role of antinuclear antibodies in systemic lupus erythematosus. Nature reviews. Rheumatology, 16(10), 565-579. https://doi.org/10.1038/s41584-020-0480-7
- Ralli, M., Angeletti, D., Fiore, M., D'Aguanno, V., Lambiase, A., Artico, M., de Vincentiis, M., & Greco, A. (2020). Hashimoto's thyroiditis: An update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential malignant transformation. Autoimmunity reviews, 19(10), 102649. https://doi.org/10.1016/j.autrev.2020.102649
- Al-Allaf, A. W., Ottewell, L., & Pullar, T. (2002). The prevalence and significance of positive antinuclear antibodies in patients with fibromyalgia syndrome: 2-4 years' follow-up. Clinical rheumatology, 21(6), 472-7. https://doi.org/10.1007/s100670200118
- Arbuckle, M. R., McClain, M. T., Rubertone, M. V., Scofield, R. H., Dennis, G. J., James, J. A., & Harley, J. B. (2003). Development of autoantibodies before the clinical onset of systemic lupus erythematosus. The New England journal of medicine, 349(16), 1526-33. https://doi.org/10.1056/NEJMoa021933
- Choi, M. Y., Clarke, A. E., St Pierre, Y., Hanly, J. G., Urowitz, M. B., Romero-Diaz, J., Gordon, C., Bae, S. C., Bernatsky, S., Wallace, D. J., Merrill, J. T., Isenberg, D. A., Rahman, A., Ginzler, E. M., Petri, M., Bruce, I. N., Dooley, M. A., Fortin, P. R., Gladman, D. D., ... Fritzler, M. J. (2019). Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort. Arthritis care & research, 71(7), 893-902. https://doi.org/10.1002/acr.23712
- Agmon-Levin, N., Damoiseaux, J., Kallenberg, C., Sack, U., Witte, T., Herold, M., Bossuyt, X., Musset, L., Cervera, R., Plaza-Lopez, A., Dias, C., Sousa, M. J., Radice, A., Eriksson, C., Hultgren, O., Viander, M., Khamashta, M., Regenass, S., Andrade, L. E., ... Shoenfeld, Y. (2014). International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Annals of the rheumatic diseases, 73(1), 17-23. https://doi.org/10.1136/annrheumdis-2013-203863
- Selmi, C., Ceribelli, A., Generali, E., Scirè, C. A., Alborghetti, F., Colloredo, G., Porrati, L., Achenza, M. I., De Santis, M., Cavaciocchi, F., Massarotti, M., Isailovic, N., Paleari, V., Invernizzi, P., Matthias, T., Zucchi, A., & Meroni, P. L. (2016). Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15 years. Autoimmunity reviews, 15(2), 162-6. https://doi.org/10.1016/j.autrev.2015.10.007
- Satoh, M., Chan, E. K., Ho, L. A., Rose, K. M., Parks, C. G., Cohn, R. D., Jusko, T. A., Walker, N. J., Germolec, D. R., Whitt, I. Z., Crockett, P. W., Pauley, B. A., Chan, J. Y., Ross, S. J., Birnbaum, L. S., Zeldin, D. C., & Miller, F. W. (2012). Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis and rheumatism, 64(7), 2319-27. https://doi.org/10.1002/art.34380
- Whiting, P. F., Smidt, N., Sterne, J. A., Harbord, R., Burton, A., Burke, M., Beynon, R., Ben-Shlomo, Y., Axford, J., & Dieppe, P. (2010). Systematic review: accuracy of anti-citrullinated Peptide antibodies for diagnosing rheumatoid arthritis. Annals of internal medicine, 152(7), 456-64; W155-66. https://doi.org/10.7326/0003-4819-152-7-201004060-00010
- European Association for the Study of the Liver (2017). EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. Journal of hepatology, 67(1), 145-172. https://doi.org/10.1016/j.jhep.2017.03.022
.avif)
.svg)
.svg)
